321 related articles for article (PubMed ID: 19813043)
1. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
Bruyère O; Collette J; Rizzoli R; Decock C; Ortolani S; Cormier C; Detilleux J; Reginster JY
Osteoporos Int; 2010 Jun; 21(6):1031-6. PubMed ID: 19813043
[TBL] [Abstract][Full Text] [Related]
2. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
Collette J; Bruyère O; Kaufman JM; Lorenc R; Felsenberg D; Spector TD; Diaz-Curiel M; Boonen S; Reginster JY
Osteoporos Int; 2010 Feb; 21(2):233-41. PubMed ID: 19436941
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.
Reginster JY; Kaufman JM; Goemaere S; Devogelaer JP; Benhamou CL; Felsenberg D; Diaz-Curiel M; Brandi ML; Badurski J; Wark J; Balogh A; Bruyère O; Roux C
Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
6. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.
Roux C; Fechtenbaum J; Kolta S; Isaia G; Andia JB; Devogelaer JP
Ann Rheum Dis; 2008 Dec; 67(12):1736-8. PubMed ID: 18713788
[TBL] [Abstract][Full Text] [Related]
7. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
[TBL] [Abstract][Full Text] [Related]
9. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.
Middleton ET; Steel SA; Aye M; Doherty SM
J Bone Miner Res; 2010 Mar; 25(3):455-62. PubMed ID: 20201000
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.
Abboskhujaeva LS; Ismailov SI; Alikhanova NM
Drugs R D; 2014 Dec; 14(4):315-24. PubMed ID: 25480348
[TBL] [Abstract][Full Text] [Related]
12. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
[TBL] [Abstract][Full Text] [Related]
13. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study.
Rizzoli R; Chapurlat RD; Laroche JM; Krieg MA; Thomas T; Frieling I; Boutroy S; Laib A; Bock O; Felsenberg D
Osteoporos Int; 2012 Jan; 23(1):305-15. PubMed ID: 21909729
[TBL] [Abstract][Full Text] [Related]
14. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.
Middleton ET; Steel SA; Aye M; Doherty SM
Osteoporos Int; 2012 Jan; 23(1):295-303. PubMed ID: 21274515
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate in osteoporosis.
Reginster JY
Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
17. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
19. Strontium ranelate: a new paradigm in the treatment of osteoporosis.
Reginster JY; Deroisy R; Jupsin I
Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204
[TBL] [Abstract][Full Text] [Related]
20. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
